These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

463 related articles for article (PubMed ID: 25794777)

  • 1. Therapeutic management of severe relapses in multiple sclerosis.
    Bevan C; Gelfand JM
    Curr Treat Options Neurol; 2015 Apr; 17(4):345. PubMed ID: 25794777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral versus intravenous steroids for treatment of relapses in multiple sclerosis.
    Burton JM; O'Connor PW; Hohol M; Beyene J
    Cochrane Database Syst Rev; 2012 Dec; 12():CD006921. PubMed ID: 23235634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma exchange in severe acute relapses of multiple sclerosis - Results from a Portuguese cohort.
    Correia I; Ribeiro JJ; Isidoro L; Batista S; Nunes C; Macário C; Borges C; Tomaz J; Sousa L
    Mult Scler Relat Disord; 2018 Jan; 19():148-152. PubMed ID: 29241141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral versus intravenous steroids for treatment of relapses in multiple sclerosis.
    Burton JM; O'Connor PW; Hohol M; Beyene J
    Cochrane Database Syst Rev; 2009 Jul; (3):CD006921. PubMed ID: 19588409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute Multiple Sclerosis Relapse.
    Berkovich RR
    Continuum (Minneap Minn); 2016 Jun; 22(3):799-814. PubMed ID: 27261683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma Exchange in a Patient with Tumefactive, Corticosteroid-Resistant Multiple Sclerosis.
    Ikeda KM; Lee DH; Fraser JA; Mirsattari S; Morrow SA
    Int J MS Care; 2015; 17(5):231-5. PubMed ID: 26472944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of Multiple Sclerosis Relapses.
    Repovic P
    Continuum (Minneap Minn); 2019 Jun; 25(3):655-669. PubMed ID: 31162310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab for relapsing-remitting multiple sclerosis.
    He D; Guo R; Zhang F; Zhang C; Dong S; Zhou H
    Cochrane Database Syst Rev; 2013 Dec; (12):CD009130. PubMed ID: 24310855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beneficial therapeutic plasma exchange response in the treatment of severe relapses in patients with multiple sclerosis.
    Mesaros S; Pekmezovic T; Martinovic V; Ivanovic J; Tamas O; Dinic M; Drulovic J
    Acta Neurol Belg; 2024 Dec; 124(6):1885-1890. PubMed ID: 39044118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasmapheresis and immunoadsorption in patients with steroid refractory multiple sclerosis relapses.
    Faissner S; Nikolayczik J; Chan A; Hellwig K; Gold R; Yoon MS; Haghikia A
    J Neurol; 2016 Jun; 263(6):1092-8. PubMed ID: 27039388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relapse prevalence, symptoms, and health care engagement: patient insights from the Multiple Sclerosis in America 2017 survey.
    Nazareth TA; Rava AR; Polyakov JL; Banfe EN; Waltrip Ii RW; Zerkowski KB; Herbert LB
    Mult Scler Relat Disord; 2018 Nov; 26():219-234. PubMed ID: 30368080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of acute relapses in multiple sclerosis.
    Berkovich R
    Neurotherapeutics; 2013 Jan; 10(1):97-105. PubMed ID: 23229226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What is new in the treatment of multiple sclerosis?
    Weinstock-Guttman B; Jacobs LD
    Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
    Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral and intravenous steroids for multiple sclerosis relapse: a systematic review and meta-analysis.
    Lattanzi S; Cagnetti C; Danni M; Provinciali L; Silvestrini M
    J Neurol; 2017 Aug; 264(8):1697-1704. PubMed ID: 28492970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral prednisone taper following intravenous steroids fails to improve disability or recovery from relapses in multiple sclerosis.
    Perumal JS; Caon C; Hreha S; Zabad R; Tselis A; Lisak R; Khan O
    Eur J Neurol; 2008 Jul; 15(7):677-80. PubMed ID: 18459972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of acute relapses in neuromyelitis optica: Steroids alone versus steroids plus plasma exchange.
    Abboud H; Petrak A; Mealy M; Sasidharan S; Siddique L; Levy M
    Mult Scler; 2016 Feb; 22(2):185-92. PubMed ID: 25921047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcome of MS relapses in the era of disease-modifying therapy.
    Stoppe M; Busch M; Krizek L; Then Bergh F
    BMC Neurol; 2017 Aug; 17(1):151. PubMed ID: 28784102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of an algorithm to detect severe MS relapses in administrative health databases.
    Marriott JJ; Chen H; Fransoo R; Marrie RA
    Mult Scler Relat Disord; 2018 Jan; 19():134-139. PubMed ID: 29223870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.